Article

First-Trimester Use of Paroxetine and Congenital Heart Defects: A Population-Based Case-Control Study

Eurocat Northern Netherlands, Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Birth Defects Research Part A Clinical and Molecular Teratology (Impact Factor: 2.09). 11/2009; 88(2):94-100. DOI: 10.1002/bdra.20641
Source: PubMed

ABSTRACT

There is a need for case-control studies of the effect of paroxetine on the occurrence of specific heart defects.
We performed a case-control study with data from a population-based birth defects registry in the Netherlands. All the children born between 1997 and 2006 were selected. Cases were defined as fetuses and children with isolated heart defects, and the controls were fetuses and children with a genetic disorder with no heart defect. We excluded children for whom there was no information on maternal medication use and deceased children and fetuses who were not examined postmortem. First-trimester exposure to paroxetine was compared between cases and controls by calculating adjusted odds ratios (AOR).
We included 678 cases with isolated heart defects and 615 controls. The first trimester exposure rate was 1.5% for cases and 1.0% for controls. After excluding mothers who used paroxetine outside the first trimester, or who had used another SSRI, we found no significantly increased risk for heart defects overall (10 exposed cases; AOR, 1.5; 95% confidence interval [CI], 0.5-4.0), but we did find a significantly increased risk for atrium septum defects (three exposed cases; AOR, 5.7; 95% CI, 1.4-23.7).
Our results suggest that the use of paroxetine in early pregnancy is associated with an increased risk of atrium septum defects. The results stress the importance of studying possible teratogenic effects of a drug, preferably in regard to well-specified malformations.

Download full-text

Full-text

Available from: Wilhelmina S Kerstjens-Frederikse
  • Source
    • "Some reviewers have concluded that there is no increased risk in first-trimester exposure [25] [26] [27], some that the evidence is conflicting [28], some that paroxetine is teratogenic and that other SSRIs are not [29], and others that there may be poor neonatal outcomes [30]. In a case-control study first-trimester exposure to paroxetine was associated with a significantly increased risk of atrial septal defects (adjusted OR ¼ 5.7; 95% CI ¼ 1.4, 24) [31]. However, in contrast, in one study there was a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine but not paroxetine [32] and in another a greater risk of septal heart defects with sertraline and citalopram but not paroxetine or fluoxetine [33]; this illustrates the confusion that can arise from such studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Observational studies of drug effects are often regarded as inadequate in providing evidence of benefits but accepted as evidence of harms. Important harms that have been suggested by observational studies include teratogenicity of selective serotonin reuptake inhibitors, suicide associated with isotretinoin, and asthma associated with paracetamol. However, in all these cases the evidence is highly variable, and factors such as confounding by indication or selection bias have not been adequately taken into account. Systematic reviews of studies that are subject to confounding are themselves similarly affected. Other examples of drug-event pairs highlighted by observational studies include glucocorticoids and atrial fibrillation, antipsychotic drugs and raised hemoglobin A1C, adverse reactions to proton pump inhibitors plus clopidogrel, psychoactive drugs and memory loss, and adverse reactions to methylphenidate. We should not jump to the conclusion that causation is implied when an event has been attributed to a medication in an observational study, unless the odds ratio is very high or the study has been designed so as to eliminate or at least reduce the likelihood of such factors as confounding and selection bias; whenever possible, studies of adverse drug reactions should be so designed from the start. Furthermore, when adverse reactions are listed in information sources, such as Summaries of Product Characteristics, the level of evidence on which they are based should be stated. If the evidence falls short of proof of an association, it may be appropriate to issue a precautionary warning, making it clear that the association has not been proven.
    Full-text · Chapter · Dec 2014
  • Source
    • "Studies with larger cohorts have shown an association between first trimester antidepressant exposure and congenital heart defects, particularly septal defects.93,94,98,111–117 Although these results have not been replicated in several other studies,51,87,90,97,100,118–124 a small increase in the risk of any cardiac malformation or septal heart defect has been consistently reported across meta-analyses (Table 3), particularly for paroxetine,105–107 and in one case fluoxetine.108 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In pregnant women with major depression, the overarching goal of treatment is to achieve or maintain maternal euthymia, thus limiting both maternal and fetal exposure to the harmful effects of untreated or incompletely treated depression. However, the absence of uniformly effective therapies with guaranteed obstetric and fetal safety makes the treatment of major depression during pregnancy among the most formidable of clinical challenges. Clinicians and patients are still faced with conflicting data and expert opinion regarding the reproductive safety of antidepressants in pregnancy, as well as large gaps in our understanding of the effectiveness of most antidepressants and nonpharmacological alternatives for treating antenatal depression. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated maternal depression during pregnancy, the effectiveness of interventions for maternal depression during pregnancy, and potential obstetric, fetal, and neonatal risks associated with antenatal antidepressant use.
    Full-text · Article · Sep 2014 · Drug, Healthcare and Patient Safety
  • Source
    • "Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used medications in pregnancy, with prescription frequency estimates in pregnant women ranging from 0.7 to 1.4 % in Nordic countries (Jimenez- Solem et al. 2013; Kieler et al. 2012) and 5–13 % in the United States (Andrade et al. 2008; Cooper et al. 2007; Ramos et al. 2008). There is accumulating evidence that mothers treated with SSRIs during pregnancy may experience increased rates of adverse reproductive outcomes (Bakker et al. 2010; Lund et al. 2009). In addition, recent studies have suggested a possible link between prenatal antidepressant exposure and neurodevelopmental outcomes including altered speech perception (Weikum et al. 2012) and motor, social–emotional and adaptive behavior (Hanley et al. 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark's health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child's risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
    Full-text · Article · May 2014 · Journal of Autism and Developmental Disorders
Show more